We have tested the hypothesis that the CysLT 1 receptor is expressed by a variety of bronchial mucosal immune cells and that the numbers of these cells increase in asthma, when stable and in exacerbations. We have applied in situ hybridization and immunohistochemistry to endobronchial biopsy tissue to identify and count inflammatory cells expressing CysLT 1 receptor mRNA and protein, respectively, and used double immunohistochemistry to identify the specific cell immunophenotypes expressing the receptor. Double-labeling demonstrated that bronchial mucosal eosinophils, neutrophils, mast cells, macrophages, B-lymphocytes, and plasma cells, but not T-lymphocytes, expressed the CysLT 1 receptor. The numbers of CysLT 1 receptor mRNA and protein positive inflammatory cells in nonsmoking, nonatopic control subjects without asthma were 13 and 16 mm Ϫ2 , respectively (median values; n ϭ 15), and were significantly greater in stable asthma (50 and 43 mm Ϫ2 , respectively; n ϭ 17; P Ͻ 0.001). Compared with stable asthma, there were further significant increases in subjects hospitalized for a severe exacerbation of their asthma (mRNA: median ϭ 113 and protein: 156 mm Ϫ2 ; n ϭ 15; P Ͻ 0.002). For the combined data of both asthma subgroups, there were strong positive correlations between the increased numbers of CD45ϩ leukocytes and the greater numbers of cells expressing CysLT 1 receptor (mRNA: r ϭ 0.60, P Ͻ 0.001; protein: r ϭ 0.73, P Ͻ 0.0001). In conclusion, a variety of immunohistologically distinct inflammatory cells express the CysLT 1 receptor in the bronchial mucosa and both these and the total number of leukocytes increase in mild stable disease and increase further when there is a severe exacerbation of asthma.
ation is supported by the effectiveness of LTRAs in inhibiting these processes (14) (15) (16) .
There are two pharmacologically defined G protein-coupled LT receptors described thus far: CysLT 1 and CysLT 2 (17, 18) . More may exist, and isoforms are now being reported (19) . The CysLT 1 receptor is the main receptor for the actions of CysLTs in the lung and the prime target for LTRAs in the treatment of asthma (17, 18, 20) and allergic rhinitis (21) (22) (23) . Figueroa and colleagues have reported CysLT 1 receptor expression in histologically normal lung tissue resected from a smoker without asthma and also its expression in peripheral blood leukocytes (17, 24) . The receptor has also been localized to nasal lavage cells obtained from symptomatic patients with seasonal allergic rhinitis (21) and in human nasal mucosa from patients with perennial rhinitis (22) . There has been no histologic description of CysLT 1 receptor gene or protein expression in the bronchial mucosa of individuals with asthma, there are no data concerning the phenotype of bronchial inflammatory cells that express it, and it is not known whether the numbers of CysLT 1 receptor-positive cells are altered in asthma.
The successful cloning of the CysLT 1 receptor (17) now provides the opportunity to apply molecular in situ hybridization (ISH) and immunohistochemical methods to endobronchial biopsies for the purposes of identifying the phenotypes of airway mucosal inflammatory cell that express it and counting the numbers of CysLT 1 receptor-positive inflammatory cells in distinct subject groups. We examine here the hypothesis that the CysLT 1 receptor is expressed by a variety of airway mucosal inflammatory cells in asthma and that the numbers of cells expressing it are increased in asthma, when stable and in association with an exacerbation. We have obtained endobronchial mucosal biopsies after obtaining informed consent, and have performed studies to locate, identify, and count cells that express the CysLT 1 receptor mRNA or protein in our three subject groups: nonatopic control subjects without asthma, subjects with mild asthma in a stable phase of their disease, and subjects with asthma who were hospitalized for an acute severe exacerbation.
MATERIALS AND METHODS

Subjects
The study conformed to the declaration of Helsinki. The institute review boards for human studies of each hospital approved the study protocols specifically written for this project and each subject or, in the case of the intubated subjects, their surrogate gave informed, written consent. There were three subject groups. Group 1 was made up of nonsmoking surgical control subjects (henceforth referred to as NSC; n ϭ 15) with normal lung function (i.e., FEV 1 Ͼ 80% of predicted; FEV 1 /FVC Ͼ 70%) who were having a surgical procedure under general anesthesia for nonbronchopulmonary disease (e.g., hysterectomy or cholecystectomy). They were nonatopic (i.e., with negative skin tests for a panel of common allergen extracts). Blood eosinophil counts were normal (i.e., within the range of 0.0-0.4 ϫ 10 9 /liter). Group 2 consisted of patients with stable asthma (S-asthma, n ϭ 17) (see Table 1 ); these were nonsmokers with intermittent, mild persistent asthma as defined clinically using Global Initiative for Asthma Guideline criteria (prebronchodilator FEV 1 of у 70% predicted and FEV 1 /FVC Ͼ 70%) (25) . All had a clinical history of asthma of at least 1 yr duration. Their asthma was controlled using short-acting ␤ 2 -agonists as required and had not received regular treatment with inhaled, oral, or injected steroids or inhaled cromolyn, nedocromil, or ketotifen for more than 3 mo, or any single dose for у 6 wk before the study start. They had not taken oral theophylline within 2 wk or long-acting ␤ 2 -agonist within 1 wk or short-acting ␤ 2 -agonist within ‫ف‬ 6 h before the study start. They had not smoked for at least a year prior to the study, and their smoking history was р 10 pack-years. Otherwise the subjects were in good health and had had no other significant disease or medication before or during the study. Each subject underwent a pre-study screening visit, in which a full clinical assessment including baseline spirometry, chest X-ray, ECG, skin prick testing to common allergens, and histamine challenge testing were performed. All the subjects demonstrated airway hyperresponsiveness to histamine with a PC 20 of р 4 mg/ml. Group 3 comprised patients with an acute severe exacerbation of asthma (E-asthma, n ϭ 15; see Table 1 ), defined as a sudden worsening of asthma symptoms (i.e., wheezing, breathlessness, chest tightness, and cough) and lung function (26) . Each had experienced one of the following features: continuous symptoms, frequent exacerbations or nighttime asthma symptoms, PEF or FEV 1 р 60% of predicted, an FEV 1 /FVC Ͻ 70%, and variability у 30%. All required hospitalization and did not respond to usual treatment requiring emergent intubation and mechanical ventilation for respiratory failure (26) . All of these patients were on ␤ 2 -agonist nebulizer and received between 1 and 3 doses of corticosteroids (Solumedro 60-80 mg/6-12 h) intravenously during the admission. All the patients in this group had a past history of allergy. All were on multiple daily controller medication before the exacerbation: all had received short-acting ␤ 2 -agonist as required, 12 of 15 had been receiving inhaled steroids, and 7 of 15 had received oral steroids ( 
Bronchoscopy and Biopsy
Biopsies from NSC subjects were taken immediately after intubation before infusion of prophylactic antibiotics. All E-asthma patients underwent bronchoscopy, and biopsies were taken within 24 h of their hospital admission. Biopsies were taken using an Olympus, type BF P10 or BF P20D (Olympus Co., Tokyo, Japan) with alligator forceps (microvasive radial jaw single use biopsy forceps, 1.8 mm external diameter; Boston Scientific Corporation, Natick, MA) from the third, fourth, and fifth order bronchial divisions of the right or left lung. Biopsies were fixed immediately in 10% formaldehyde at room temperature. After processing, they were embedded in paraffin wax. Serial sections of 5 m thick were cut and stained with hematoxylin and eosin (H&E) for assessment initially of their size and morphology.
Positive and Negative Control Cells
Cos-7 monkey kidney cells (COS cells) transfected with CysLT 1 receptor or CysLT 2 receptor cDNA (17) and processed in the same manner as our paraffin-embedded biopsy tissue, were used to confirm the specificity of the CysLT 1 receptor probe and antisera. They were also used as positive and negative controls for the following ISH and immunohistochemistry (IHC) procedures, respectively (17, 18, 24) .
Nonisotopic ISH
CysLT 1 receptor cDNA (1,033 bp) in pcDNA3.1 zeoϩ vector (Merck Research Laboratories, West Point, PA) was subcloned into PGEM-3Z vector. The nucleic acid sequences of the CysLT 1 receptor probe have been described previously (17) . PGEM-3Z containing CysLT 1 receptor cDNA was expanded in JM109 Escherichia coli-competent cells. The antisense CysLT 1 and sense CysLT 1 receptor probes were linearized with HindIII and XbaI, respectively.
Preparation of cRNA probes. Digoxigenin (Dig)-labeled antisense and sense complementary ribonucleic acid (cRNA) probes were generated from cDNA using T7 and SP6 RNA transcription polymerises, respectively. To check transcription efficiency and quantify the probe, 1 l Dig-RNA was taken for electrophoresis in 1.2% agarose gel, after which it was stored at Ϫ80ЊC.
Prehybridization. The sections were dewaxed and incubated with proteinase K to permeabilize the cells. Hybridization buffer (2ϫ Denhardt's solution, 50 g/ml salmon sperm DNA, 100 g/ml yeast tRNA, 50% formamide) containing 100 ng/ml Dig-labeled cRNA probe, was added and incubated at 42ЊC overnight. Sense probes were used as the most appropriate negative control. Slides were washed in different concentrations of sodium chloride/trisodium citrate (SSC) and incubated in 20 g/ml RNase A. The remaining probe hybridized with the mRNA of interest was localized with an anti-Dig antibody conjugated to alkaline phosphatase. Detection was performed by addition of 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (NBT/ BCIP) substrate following an incubation of 30-60 min to give a blue/ black end-product. The nuclear counterstain used was nuclear fast red.
IHC
CysLT 1 receptor protein expression in the bronchial biopsies was detected by IHC, applying the EnVision-alkaline phosphatase (EV-AP) technique according to EnVision AP Kit (DAKO Ltd, Cambridge, UK). The selective, affinity purified, anti-human polyclonal antisera for CysLT 1 receptor was raised in a goat against purified full-length recombinant CysLT 1 receptor (17) . We replaced the primary antibody with normal goat serum as a further negative control.
The paraffin sections were blocked with 20% normal rabbit serum (DAKO) in Tris-buffered saline (TBS) pH7.6. The sections were then immunostained with CysLT 1 receptor polyclonal antibodies at 1:3,000 at room temperature, washed, and incubated with rabbit anti-goat immunoglobulins in TBS with 10% normal goat serum. After washing, the sections were incubated with AP-conjugated goat anti-rabbit immunoglobulin. After a further wash, bound AP was detected as a red product following incubation with Naphthol AS-MX phosphate and 1 mg/ml New Fuschin. The slides were counterstained with hematoxylin to provide morphologic detail and then mounted in Aqua perm mounting medium. The alkaline phosphatase anti-alkaline phosphatase (APAAP) was used to label CD45ϩ inflammatory cells, eosinophils, and neutrophils using mouse anti-human CD45, leucocyte common antigen mAb (DAKO M0701), mouse anti-EG2 (Pharmacia and Upjohn Ltd, Milton Keynes, UK), and mouse anti-neutrophil elastase (DAKO Ltd), respectively. Double immunohistofluorecence staining was performed to determine which phenotype(s) of inflammatory cell expressed the CysLT 1 receptor protein and to determine the colocalization of CysLT 1 receptor protein and smooth muscle actin in the E-asthma group. Immunohistochemistry for the CysLT 1 -receptor was similarly performed using a polyclonal goat anti-full length recombinant human CysLT 1 -receptor antisera previously described (17, 24) . The primary anti-human antibodies for the phenotypic identification of inflammatory cells coexpressing CysLT 1 -receptor were mouse anti-EG2 for eosinophils, anti-neutrophil elastase for neutrophils, anti-mast cell tryptase for mast cells (DAKO), anti-CD3 for T-lymphocytes (Novocastra, Newcastle-upon-Tyne, UK), anti-CD45RO (clone OPD4) for activated CD4ϩ T-lymphocytes (DAKO), anti-CD8 for cytotoxic/suppressor T cells (DAKO), anti-CD64 marking cells of the monocyte lineage and anti-CD19, a marker for B cells and B-cell precursors (Pharmingen, San Diego, CA), and anti-plasma cell-specific antigen (Novocastra) for plasma cells. A marker for smooth muscle actin (Zymed Laboratories, San Francisco, CA) was used in combination with CysLT 1 -receptor antisera for simultaneous detection of bronchial smooth muscle and expression of this receptor. Bound antibody was detected with a combination of the appropriate fluorescein isothiocyanate or Texas red-labeled donkey secondary antisera (Jackson Immunoresearch, West Grove, PA). Sections were counterstained with DAPI. Images were acquired using a Leica TCS-SP confocal microscope with lasers giving excitation wavelengths of 351-364 nm, 488 nm, 568 nm (Leica Microsystems UK Ltd, Milton Keynes, UK).
Quantification
Slides were coded to avoid observer bias. Areas of subepithelium, excluding those areas with mucus-secreting glands and bronchial smooth muscle, were assessed using an Apple Macintosh computer and Image 1.5 software (Apple Computer, Cupertino, CA). CysLT 1 receptor mRNA ϩ and proteinϩ cells, CD45ϩ inflammatory cells (as an overall marker of the leukocyte population), eosinophils, and neutrophils in the entire subepithelial area of the biopsy were counted using a Leitz Dialux 20 light microscope (Leitz, Wetzlar, Germany) working at ϫ200 magnification and fitted with an eyepiece graticule divided into 100 squares. Two to three bronchial biopsies for each subject were measured and counted to take account of the within subject variability: the average of the counts for each subject was used for statistical analyses.
Statistical Analyses
The data for cell counts of bronchial biopsies were expressed as the number of cut cell profiles with a nucleus visible (i.e., positive cells) per mm 2 of the subepithelium. The coefficient of variation (CV ϭ SD/ mean ϫ 100) was used to express the error of repeat counts. The unpaired Student's t test was used for the statistical analyses of age and lung function data. The Mann-Whitney U-test was applied to test for differences between the groups in respect of cell counts as these data were non-normally distributed. Spearman's rank correlation was used as a test for correlation between numbers of EG2-positive eosinophils, neutrophils, or CD45ϩ leukocytes and cells positive for CysLT 1 receptor mRNA or protein. A P value of Ͻ 0.05 was accepted as indicating a significant difference in the t test or Mann-Whitney U-tests. For Spearman's rank correlation, a value of P Ͻ 0.01 was used as the threshold for statistical significance following application of Bonferoni's correction for the multiple analyses we performed.
RESULTS
Demography
The demographic characteristics of the NSC and subjects with S-asthma or E-asthma from whom bronchial biopsies were obtained are summarized in Table 1 . NSC and E-asthma groups were similar with regard to age. However, those in the S-asthma group were significantly younger than in either the NSC and E-asthma groups (P Ͻ 0.01). Both the FEV 1 % of predicted and FEV 1 /FVC values of the E-asthma group were significantly lower than those of the NSC and S-asthma groups (P Ͻ 0.001). The subjects in the NSC and S-asthma groups, and 14 of 15 subjects in E-asthma group, were nonsmokers.
Biopsy Quality
The endobronchial biopsies were 1-2 mm in diameter and of good quality defined by examination of H&E staining on the basis of size ‫ف(‬ 1 mm 2 ) and, depending on the subject group, the presence in the NSC group of intact pseudostratified, ciliated columnar epithelium with relatively few goblet cells identification. Compared with the NSC group, the biopsies from S-asthma and E-asthma subjects showed the homogenous thickening of the epithelial reticular basement membrane characteristic of asthma. The epithelium of the asthma groups typically had goblet cell hyperplasia or focal squamous metaplasia and subepithelial infiltration by inflammatory cells, especially eosinophils.
CysLT 1 Receptor mRNA and Protein Expression
Both ISH (data not shown) and IHC showed moderate to strong positive staining for the CysLT 1 receptor mRNA and protein in the CysLT 1 receptor-cDNA transfected COS cells ( Figure 1A) . CysLT 2 receptor-transfected cells showed only weak crossreactivity with CysLT 1 receptor RNA probe (data not shown), and were negative after the CysLT 1 receptor antisera ( Figure 1B) . In contrast, CysLT 2 receptor antisera showed a strong fluorescent signal on the CysLT 2 receptor-transfected COS cells. There was an absence of signal with the mRNA "sense" controls (data not shown) and no immunostaining of COS CysLT 1 receptortransfected cells when the primary antibody was replaced by normal goat serum ( Figure 1C) .
Localization of the CysLT 1 Receptor
Inflammatory cells in the subepithelium stained strongly for both CysLT 1 receptor mRNA and protein. There were relatively few in the NSC group (Figures 2A and 3A) and obviously more in both the S-asthma and E-asthma groups ( Figures 2B and 3B) . Occasionally, CysLT 1 receptor-immunopositive inflammatory cells were seen to have infiltrated the surface epithelium ( Figure 3B ). By comparison with the negative controls, vascular endothelium across all groups was positive for both CysLT 1 receptor mRNA and protein (see Figures 2A, 2B , and 3A), whereas epithelial positivity was focal and of weak intensity in the control subjects (Figures 2A and 3A ) and moderate to strong in the subjects with asthma ( Figures 2B and 3B ). Bronchial biopsies from the E-asthma group, either hybridized with the sense CysLT 1 receptor mRNA probe or those undergoing the immunostaining procedure but without the primary CysLT 1 receptor antiserum, were included and did not stain ( Figures 2C and 3C ).
In the E-asthma group, double immunofluorescence staining identified EG2ϩ eosinophils ( Figures 4A-4C CD3ϩ ( Figure 5 ), CD4ϩ, and CD8ϩ T-lymphocytes were negative with the CysLT 1 receptor antisera.
As expected, airway smooth muscle myocytes stained positively for the CysLT 1 receptor but, unexpectedly, many showed relatively weak and, in some instances, no staining for either CysLT 1 receptor mRNA or protein. This variability of smooth muscle myocyte positivity was seen across all subject groups. Using the same techniques applied previously to frozen lung material (17), we were able to identify, in our paraffin waxembedded material, colocalization of the immunostaining for the CysLT 1 receptor with a few, but not all, areas of immunostaining for actin, as shown in a biopsy from a patient with an exacerbation of asthma ( Figures 6A-6C ). In the patient with asthma from whom we had previously obtained an open lung biopsy (which allowed us to examine greater amounts of airway smooth muscle than previously possible), we found a similar pattern of variability to that seen in the relatively smaller bronchial biopsies. By comparison to the bronchiolar smooth muscle of this surgical case, the adjacent inflammatory cells were strongly positive for CysLT 1 receptor mRNA (Figures 7A and 7B) . In some cases, background nonspecific staining of adjacent elastic tissue was intense, such that it obscured the weak staining of the smooth muscle ( Figure 7B ). The morphology and elastic-van Gieson staining in the open lung biopsy material confirmed that it was the elastic component, surrounding and intermingled with the myocytes that stained rather than the area corresponding to bronchiolar smooth muscle myocytes per se ( Figure 7C ).
Quantification of Leukocytes and Cells Expressing the CysLT 1 Receptor
The coefficients of variation (CV) for repeat counts of cells immunopositive for CysLT 1 receptor mRNA and protein by one observer were 5% and 6%, respectively. The data for the counts of the numbers of sub-epithelial cells expressing mRNA or protein are summarized in Figure 8 . Compared with NSC, the values for the S-asthma group were significantly greater for both CysLT 1 receptor mRNA ϩ (3.8-fold) (P Ͻ 0.001) and proteinϩ cells (2.7-fold) (P Ͻ 0.001). The numbers of CysLT 1 receptor mRNA ϩ and proteinϩ cells in exacerbations of asthma were significantly higher than those of the stable asthma group, 2.3-fold (P Ͻ 0.002) and 3.6-fold (P Ͻ 0.001), respectively (Figure 8 
Correlations
The number of cells expressing CysLT 1 receptor mRNA per mm 2 subepithelial area in each groups correlated positively with the number expressing the receptor protein (r ϭ 0.53-0.67, P Ͻ 0.01 Spearman Rank Correlation). There were no significant associations between the numbers of EG2-positive eosinophils or neutrophils and the numbers of cells expressing CysLT 1 receptor mRNA or protein in either the S-asthma or E-asthma groups. However, there were strong positive correlations between the numbers of CD45ϩ leukocytes and the numbers of cells expressing CysLT 1 receptor mRNA or protein when the data for the S-asthma and E-asthma groups were combined (mRNA: r ϭ 0.60, P Ͻ 0.0001; Protein: r ϭ 0.73, P Ͻ 0.001) (Figure 9 ) and the significant positive correlations remained for the protein when each asthma subgroup was considered alone (S-asthma: r ϭ 0.50, P Ͻ 0.005; E-asthma: r ϭ 0.75, P Ͻ 0.002). 
DISCUSSION
These data are the first in asthma to demonstrate both mRNA and protein expression for the CysLT 1 receptor in bronchial mucosal inflammatory cells. Apart from bronchial (CD3ϩ) T-lymphocytes (including CD4 and CD8 subsets) that do not express the CysLT 1 receptor, we have identified a variety of other bronchial inflammatory cells, including eosinophils, neutrophils, mast cells, macrophages, B-lymphocytes, and plasma cells that do express it. Moreover, in a comparison with nonsmoking control subjects without asthma, we show that there are greater numbers of CysLT 1 receptor-positive cells in stable asthma and further significant increases in individuals with asthma hospitalized for an acute severe exacerbation. Some of these data have been presented by us previously, but only in preliminary abstract form (27) .
The CysLT 1 receptor was first characterized by Lynch and colleagues, and receptor mRNA was shown by ISH of normal lung to be expressed in both inflammatory and smooth muscle cells (17) . In addition, following the development of a CysLT 1 receptor-specific antisera, IHC of snap-frozen histologically normal lung biopsy samples showed localized the receptor protein to interstitial macrophages and bronchiolar smooth muscle (24) . CysLT 1 receptor expression was also reported in peripheral blood: pregranulocyte CD34ϩ (progenitor) cells, eosinophils, monocytes, and pre-B cells but not CD4ϩ nor CD8ϩ T cells. Double labeling immunohistochemical techniques were subsequently applied to nasal turbinate tissue from patients suffering persistent nasal obstruction, refractory to treatment, demonstrating that mast cells, neutrophils, and vascular endothelial cells also expressed the CysLT 1 receptor (22) . Moreover, the immunopositivity for both CysLT 1 and CysLT 2 receptor protein was detected on surface and gland epithelium of nasal biopsies from patients with aspirin-sensitive and aspirin-tolerant rhinosinusitis, although expression of CysLT 2 significantly exceeded that of CysLT 1 (28) .
Until now, there have been no studies of asthmatic bronchi, the most relevant target tissue for the anti-asthma actions of LTRAs, and there has been no quantitative histologic report of cells expressing this receptor in individuals with asthma. On the basis of our present description of the presence of CysLT 1 receptor-positive cells in asthmatic bronchial mucosa, we concur with the previously reported colocalization studies of nonasthma tissues and of peripheral blood cells and, in addition, confirm the absence of its localization to T-lymphocytes, including the CD4 and CD8 T cell subsets present in bronchial tissue. This is the first report of CysLT 1 receptor positivity in asthmatic bronchial tissue and the first to describe its colocalization to plasma cells.
Our findings help us to understand why several phenotypes of inflammatory cell, such as neutrophils and eosinophils, are recruited to the bronchial mucosa in response to experimental inhalation of leukotrienes (9) . Moreover, there is a positive correlation between the recruitment of increasing numbers of leukocytes and those expressing CysLT 1 receptor. This argues in favor of the tissue accumulation in asthma of greater numbers of a variety of CysLT 1 receptor-positive leukocytes through recruitment rather than by novel expression or upregulation of this receptor on pre-existing mucosal cells. Moreover, the lack of association between the numbers of cells expressing CysLT 1 receptor mRNA or protein and the numbers of neutrophils or eosinophils indicates that cells other than these are being recruited to contribute to the statistically significant correlation we report. Our study did not aim nor was it designed to determine the functional consequences of the increased numbers of CysLT 1 receptor-positive leukocytes. However, our study does demonstrate that the targets for leukotriene receptor antagonists (LTRA) are present in the bronchial mucosa, and that they increase in asthma and in association with exacerbations. Clinically we consider it reasonable to speculate that treatment with LTRA in these circumstances might well attenuate any functional consequence of an increase in their number.
Previously we have reported that bronchial smooth muscle expresses the CysLT 1 receptor (17) . However, on closer inspection in the present study, we found that while a few myocytes did so, others often only weakly expressed the receptor or did not express either its mRNA or protein at all. This contrasted with the intense reaction product seen in adjacent inflammatory cells. We were initially surprised at this finding because the CysLT 1 receptor is a member of the Gq-coupled receptor subfamily, which includes the H 1 histamine, B 2 bradykinin, and endothelin (ET) A -receptors identified in cultured airway smooth muscle cells (29) . Studies in vivo or ex vivo have demonstrated that these receptors bind their agonists to induce airway smooth muscle contraction (29) . We have not found reference to another G protein-coupled receptor that mediates contraction of airway smooth muscle but that is not expressed via IHC and ISH. Thus, while these results may challenge our expectations and current dogma, we wish to keep an open mind and consider these results to be of interest to others in the field. Clearly there is a need for follow-up work with a focus on these findings in muscle.
We conclude that our data support our hypothesis and highlight, for the first time, the variety of CysLT 1 receptor-positive inflammatory cells that may be regulated by the actions of CysLTs or inhibited by the effects of LTRAs in the asthmatic bronchial mucosa. These targets include: eosinophils, neutrophils, mast cells, monocytes, B-(but not T-) cells, and plasma cells. Moreover, in association with an increased recruitment of leukocytes, there is a significant increase of CysLT 1 receptorpositive cells in the bronchial mucosa of individuals with asthma and a further increase in those experiencing a severe exacerbation of their asthma.
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